DGAP-News: Eckert & Ziegler expands cooperation program with drug developers in the field of nuclear medicine


 
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Alliance Eckert & Ziegler expands cooperation program with drug developers in the field of nuclear medicine 03.02.2016 / 11:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Berlin, February 3, 2016 - Eckert & Ziegler AG, a specialist for isotope-based applications in medicine, science and industry, is expanding its cooperation program with promising drug developers in the field of nuclear medicine and will support Curasight, a spin-off based on research by the group of Professor Andreas Kjaer at the National University Hospital (Rigshospitalet) and University of Copenhagen, in obtaining market clearance for its uPAR breast cancer diagnostic agent. To do so, Eckert & Ziegler - represented by its Radiopharma segment - will focus mainly on the development and validation of the pharmaceutical production process and leverage its isotope laboratories and global infrastructure for this purpose. The pre-clinical and clinical trials, however, will continue to be managed from Denmark. In exchange for its services, Eckert & Ziegler will receive minority interests on a step by step basis. To a minor extent, the Group also will commit to a financial investment. However, the main contribution to the increase in Curasight's value remains the experience with the pitfalls of the approval process and the special requirements in the field of radiopharmaceuticals. "Many international drug developers have already taken advantage of our services, including Octreopharm Sciences GmbH, which is developing diagnostic and therapeutic agents for the treatment of neuroendocrine tumors. Last year, Octreopharm was also successfully sold to the French pharmaceutical company IPSEN," Dr. André Heß, Member of the Executive Board of Eckert & Ziegler AG and responsible for the Radiopharma segment, explains. "We look forward to a fruitful collaboration with Eckert & Ziegler AG and believe the two companies are a perfect match", says Morten Persson, CEO and co-founder, Curasight. The rising demand for nuclear medicine imaging methods (PET/CT) and the trend toward personalized medicine are leading more and more small, highly qualified drug developers for radiopharmaceuticals to enter the market. Eckert & Ziegler has decades of experience in isotope technology, allowing it to help these new companies develop their medicinal products. The support provided includes the use of isotope laboratories as well as the complete development of radiopharmaceutical production and testing methods (CMC) by Eckert & Ziegler. Curasight has successfully guided the medicinal product known as uPAR (Ga-68-NOTA-AE105) through clinical phase I. As a Ga-68-based radiodiagnostic agent, it is primarily intended to diagnose breast cancer. The current practice for evaluating diagnostic findings often entails removing the sentinel lymph node surgically and examining the tissue. By performing a biopsy of the lymph node, experts can identify whether a tumor has already metastasized and then determine what the options are for the further course of treatment. In the future, the new medicinal product will aim to make performing these biopsies unnecessary in many cases. Curasight's aim in developing this product is to make it possible with the help of a PET scan to determine in a non-invasive fashion the extent to which metastases have formed in the sentinel lymph node and elsewhere, and whether the lymph node actually needs to be removed. By receiving an individual diagnosis that is tailored to their specific case, many women with breast cancer can be spared unpleasant side effects. It would also reduce the overall examination time. With approximately 1.7 million new cases per year across the globe, breast cancer is the second most common type of cancer (WHO World Cancer Report 2014). Each year, some 70,000 women in Germany alone are diagnosed with breast cancer. Apart from Eckert & Ziegler, SEED Capital Denmark − Denmark's largest early stage venture fund − is also an investor in Curasight. With around 700 employees, Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) is one of the world's largest providers of isotope technology components for radiation therapy and nuclear medicine. For further information or questions, please contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin, Germany Tel.: +49 30 941084-138, [email protected], www.ezag.de --------------------------------------------------------------------------- 03.02.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Eckert & Ziegler Strahlenund Medizintechnik AG Robert-Rössle-Str.10 13125 Berlin Germany Phone: 49 30 941084-138 Fax: 49 30 941084-112 E-mail: [email protected] Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Listed: Regulated Market in Frankfurt (Prime Standard), Stuttgart; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich End of News DGAP News Service --------------------------------------------------------------------------- 434335 03.02.2016


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 138,63 168,71 178,49 176,14 180,44 222,26 246,09
EBITDA1,2 26,62 32,14 43,13 44,64 57,04 55,52 58,83
EBITDA-Marge3 19,20 19,05 24,16 25,34 31,61 24,98
EBIT1,4 17,97 23,39 32,06 33,69 47,45 44,54 45,45
EBIT-Marge5 12,96 13,86 17,96 19,13 26,30 20,04 18,47
Jahresüberschuss1 15,12 16,89 22,48 23,11 34,66 29,75 26,77
Netto-Marge6 10,91 10,01 12,59 13,12 19,21 13,39 10,88
Cashflow1,7 26,83 21,21 40,43 36,79 33,86 34,30 47,40
Ergebnis je Aktie8 0,70 0,78 1,07 1,11 1,66 1,41 1,26
Dividende8 0,20 0,30 0,42 0,45 0,50 0,50 0,17
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

INVESTOR-INFORMATIONEN
©boersengefluester.de
Eckert & Ziegler
WKN Kurs in € Einschätzung Börsenwert in Mio. €
565970 37,220 Halten 788,02
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
23,26 26,33 0,89 40,95
KBV KCV KUV EV/EBITDA
3,56 16,63 3,20 12,87
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,50 0,05 0,13 28.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
14.05.2024 09.08.2024 14.11.2024 22.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-10,57% 0,20% -9,88% -26,00%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Eckert & Ziegler Strahlen- und Medizintechnik AG  ISIN: DE0005659700 können Sie bei EQS abrufen


Medtech , 565970 , EUZ , XETR:EUZ